Lexaria Bioscience (LEXX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lexaria Bioscience Corp. has appointed Michael Shankman as its new Chief Financial Officer, marking a strategic move as the company gears up for significant growth in 2025. Shankman, who is familiar with Lexaria’s operations through previous consulting work, brings extensive experience in financial leadership from various industries. His appointment is expected to bolster Lexaria’s executive team as they advance in pharmaceutical research and their patented drug delivery technology, DehydraTECH.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.